Apogee Therapeutics, Inc.

APGE

NASDAQBiotechnology

+402.2%

since IPO

IPO Price

$17.00

Current Price

$85.37

Return

+402.2%▲

Market Cap

$6.4B

IPO Date

Jul 14, 2023

Lockup End

Jan 10, 2024

Lockup Status

Lockup expired 840days ago

Price Performance

Stock price vs IPO price over time (sample data)

Stock Price

IPO Price

Lockup End

Performance Summary

First Day

N/A

1 Month

N/A

3 Months

N/A

6 Months

N/A

1 Year

N/A

Since IPO

+402.2%

Apogee Therapeutics, Inc. (APGE) — IPO Analysis

By Kian O Connor | Updated 4/29/2026

Company Overview

Apogee Therapeutics, Inc. (ticker: APGE) specializes in brand development while maintaining strategic capabilities in market positioning, positioning itself within the Biotechnology sector through operational excellence and cost-effective alternatives. The company has developed its operations around innovation focus, creating market differentiation through specialized expertise and hybrid pricing model that supports sustainable growth and customer relationship development. The company completed its public offering on 2023-07-14, accessing capital markets during digital transformation trends within the Biotechnology landscape. The IPO timing reflected the company's strategic positioning and growth trajectory, with market reception emphasizing management's execution capabilities and the company's approach to brand development as key value creation drivers in an evolving competitive environment. Post-IPO trading performance has demonstrated strong market reception and sustained investor interest reflecting confidence in growth strategy execution. Market assessment focuses on the company's operational excellence and strategic emphasis on market positioning as indicators of long-term competitive positioning within the Biotechnology sector, with investors evaluating operational execution and market opportunity capture relative to industry development trends. The lockup period expires May 14, 2024, providing market insights into management and early investor confidence in strategic direction and competitive positioning. Given the company's focus on brand development and emphasis on innovation focus, insider trading decisions will likely reflect assessments of execution progress, competitive dynamics, and growth opportunity realization within the evolving Biotechnology market landscape.

Performance Overview

Since going public at $17.00 per share on Jul 14, 2023, Apogee Therapeutics, Inc. shares have gained 402.2%, rewarding investors who participated in the IPO. The stock currently trades at $85.37, giving the company a market capitalization of $6.4B.

Lockup Expiration

The lockup period for Apogee Therapeutics, Inc. expired 840 days ago on Jan 10, 2024. Insiders and early investors are now free to sell their pre-IPO shares. The post-lockup trading period is often volatile as the market absorbs any additional supply from insider selling.

Industry Context

Apogee Therapeutics, Inc. operates in the Biotechnology sector, which has seen varied IPO activity in recent years. The company is headquartered in the United States and is classified under SIC code . Understanding the competitive landscape and sector dynamics is essential for evaluating the long-term prospects of any newly public company in this space. Investors should consider broader market conditions, sector-specific trends, and company fundamentals when assessing APGE as an investment.

Trading History

Apogee Therapeutics, Inc. is actively trading in the public markets with a current share price of $85.37. The company went public at $17.00 per share, resulting in gains of 402.2% for IPO investors. With a current market capitalization of $6.4B, Apogee Therapeutics, Inc. continues to establish its presence as a publicly traded entity in the Biotechnology.

Important Disclaimer

This analysis of Apogee Therapeutics, Inc. (APGE) is provided for informational purposes only and should not be construed as investment advice. All data is sourced from SEC EDGAR filings and public market feeds. Past performance is not indicative of future results. Investors should conduct their own due diligence and consult with a qualified financial advisor before making investment decisions. IPOLockup.io is an independent research platform with no financial interest in any of the companies covered.

Insider Selling Activity

Estimated insider trading activity around lockup expiry period (sample data)

2

Pre-Expiry Average

Minimal

79

Expiry Day

Very High

52

Post-Expiry (30d)

High

Activity Heatmap

60 days before/after lockup expiry

Intensity Scale:

Minimal

Low

Moderate

High

Very High

Lockup Expiry

About This Data

This heatmap shows estimated insider selling activity based on typical patterns around lockup expiry periods. Actual data would be derived from SEC Form 4 filings. Higher intensity indicates more insider transactions, which may correlate with increased selling pressure and potential stock price volatility.

Similar IPOs

Companies with similar industry, market cap, or IPO timing

Same IndustrySame ExchangeSimilar Size

CAI

Caris Life Sciences, Inc.

Same IndustrySame ExchangeSimilar Size

Same IndustrySame ExchangeSimilar Size

Same IndustrySame ExchangeSimilar Size

Same IndustrySame ExchangeSimilar Size

Same IndustrySame ExchangeSimilar Size

Want to compare these IPOs side by side?

Compare Tool →

Related IPOs

Ticker	Company	Industry	IPO Date	IPO Price	Current	Return
EVMN	Evommune, Inc.	Biotechnology	Nov 6, 2025	$16.00	$25.58	+59.9%
MPLT	MapLight Therapeutics, Inc.	Biotechnology	Oct 27, 2025	$17.00	$30.31	+78.3%
LBRX	LB Pharmaceuticals Inc	Biotechnology	Sep 11, 2025	$15.00	$31.38	+109.2%
CURX	Curanex Pharmaceuticals Inc	Biotechnology	Aug 26, 2025	$4.00	$0.43	-89.3%
CAI	Caris Life Sciences, Inc.	Biotechnology	Jun 18, 2025	$21.00	$18.44	-12.2%
MENS	Jyong Biotech Ltd.	Biotechnology	Jun 17, 2025	N/A	$2.17	N/A
AARD	Aardvark Therapeutics, Inc.	Biotechnology	Feb 13, 2025	$16.00	$5.59	-65.1%
SION	Sionna Therapeutics, Inc.	Biotechnology	Feb 7, 2025	$18.00	$39.59	+119.9%